Biogen publishes data on its Alzheimer’s drug in a little-known journal

When it comes to Biogen’s controversial Alzheimer’s drug Aduhelm, even publishing the data is steeped in drama.

The key data that led to Aduhelm’s approval by the Food and Drug Administration were finally published Wednesday, more than two years after they were first described in a press release.

But in a highly irregular step for an important clinical trial, the data were published not in a major journal but in the little-known Journal of the Prevention of Alzheimer’s Disease. That has critics worried that Biogen has found a low-stakes forum for a study that deserves scrutiny and debate.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$20

for 3 months, then $399/year

$20 for 3 months Get Started

Then $399/year

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

To read the rest of this story subscribe to STAT+.

Subscribe

Log In